{"sequenceId":"845366293045","id":"34207237364","language":"English","title":"Somewhat Favorable Media Coverage Somewhat Unlikely to Affect BeiGene (BGNE) Stock Price","content":"News stories about BeiGene (NASDAQ:BGNE) have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BeiGene earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 49.1422050671024 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.    Shares of NASDAQ BGNE traded up $3.93 during trading on Friday, reaching $204.05. 455,622 shares of the stock traded hands, compared to its average volume of 366,516. The stock has a market capitalization of $10.47 billion, a PE ratio of -91.50 and a beta of 0.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.18 and a quick ratio of 11.12. BeiGene has a 52-week low of $38.01 and a 52-week high of $204.96.    Get BeiGene alerts:      BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.41). The company had revenue of $32.54 million during the quarter, compared to analyst estimates of $16.88 million. During the same quarter last year, the business earned ($1.27) earnings per share.  equities analysts expect that  BeiGene will post -8.4 EPS for the current fiscal year.      Several brokerages have issued reports on BGNE. ValuEngine raised BeiGene from a “hold” rating to a “buy” rating in a research note on Friday. Maxim Group boosted their price objective on BeiGene from $200.00 to $225.00 and gave the company a “buy” rating in a report on Friday, May 18th. Zacks Investment Research downgraded BeiGene from a “hold” rating to a “sell” rating in a report on Monday, May 14th. Credit Suisse Group assumed coverage on BeiGene in a report on Monday, May 14th. They set an “outperform” rating for the company. Finally, Piper Jaffray Companies began coverage on BeiGene in a report on Friday, April 13th. They set an “overweight” rating and a $200.00 price target for the company. One investment analyst  has rated the stock with a sell rating, one  has issued  a hold rating, eight have issued  a buy rating and one  has issued  a strong buy rating to the stock. The stock  has an average rating of “Buy” and an average target price of $173.00.    In other BeiGene news, CFO Howard Liang sold 10,872 shares of the firm’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $157.07, for a total value of $1,707,665.04. Following the sale, the chief financial officer now owns 15,872 shares of the company’s stock, valued at approximately $2,493,015.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . Company insiders own  19.90% of the company’s stock.    About BeiGene    BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.","contentWithMarkup":"News stories about BeiGene (NASDAQ:BGNE) have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BeiGene earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 49.1422050671024 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.    Shares of NASDAQ BGNE traded up $3.93 during trading on Friday, reaching $204.05. 455,622 shares of the stock traded hands, compared to its average volume of 366,516. The stock has a market capitalization of $10.47 billion, a PE ratio of -91.50 and a beta of 0.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.18 and a quick ratio of 11.12. BeiGene has a 52-week low of $38.01 and a 52-week high of $204.96.    Get BeiGene alerts:      BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.41). The company had revenue of $32.54 million during the quarter, compared to analyst estimates of $16.88 million. During the same quarter last year, the business earned ($1.27) earnings per share.  equities analysts expect that  BeiGene will post -8.4 EPS for the current fiscal year.      Several brokerages have issued reports on BGNE. ValuEngine raised BeiGene from a “hold” rating to a “buy” rating in a research note on Friday. Maxim Group boosted their price objective on BeiGene from $200.00 to $225.00 and gave the company a “buy” rating in a report on Friday, May 18th. Zacks Investment Research downgraded BeiGene from a “hold” rating to a “sell” rating in a report on Monday, May 14th. Credit Suisse Group assumed coverage on BeiGene in a report on Monday, May 14th. They set an “outperform” rating for the company. Finally, Piper Jaffray Companies began coverage on BeiGene in a report on Friday, April 13th. They set an “overweight” rating and a $200.00 price target for the company. One investment analyst  has rated the stock with a sell rating, one  has issued  a hold rating, eight have issued  a buy rating and one  has issued  a strong buy rating to the stock. The stock  has an average rating of “Buy” and an average target price of $173.00.    In other BeiGene news, CFO Howard Liang sold 10,872 shares of the firm’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $157.07, for a total value of $1,707,665.04. Following the sale, the chief financial officer now owns 15,872 shares of the company’s stock, valued at approximately $2,493,015.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . Company insiders own  19.90% of the company’s stock.    About BeiGene    BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.","tags":[],"publishedDate":"2018-06-03T03:54:42Z","harvestDate":"2018-06-02T21:55:16Z","estimatedPublishedDate":"2018-06-02T21:55:16Z","url":"http://ct.moreover.com/?a=34207237364&p=1u0&v=1&x=xnI2oasyYE2j-xY0-FF_tA","originalUrl":"https://ledgergazette.com/2018/06/02/beigene-bgne-receives-daily-news-sentiment-score-of-0-03.html","outboundUrls":["https://www.marketbeat.com/stocks/NASDAQ/BGNE/","http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=BGNE","http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.sec.gov/Archives/edgar/data/1651308/000117911018004691/xslF345X03/edgar.xml"],"wordCount":"558","dataFormat":"text","duplicateGroupId":"34207237364","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Finance latest","group":"Finance"}],"companies":[{"name":"BeiGene Ltd","symbol":"BGNE","exchange":"NAS","isin":"US07725L1026","titleCount":0,"contentCount":1,"primary":true},{"name":"BeiGene Ltd","symbol":"49BA","exchange":"BER","isin":"US07725L1026","titleCount":0,"contentCount":1,"primary":true},{"name":"BeiGene Ltd","symbol":"49BA","exchange":"MUN","isin":"US07725L1026","titleCount":0,"contentCount":1,"primary":true},{"name":"BeiGene Ltd","symbol":"49BA","exchange":"FRA","isin":"US07725L1026","titleCount":0,"contentCount":1,"primary":true},{"name":"BeiGene Ltd","symbol":"49BA","exchange":"STU","isin":"US07725L1026","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX1","exchange":"FRA","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX","exchange":"FRA","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX","exchange":"DUS","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX1","exchange":"BER","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX","exchange":"BER","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX","exchange":"HAM","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX","exchange":"MUN","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX","exchange":"STU","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX1","exchange":"STU","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX1","exchange":"ETR","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSGN","exchange":"SWX","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX","exchange":"ETR","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CS","exchange":"NYS","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSGKF","exchange":"PINX","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CS","exchange":"BUE","isin":"ARDEUT112422","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CS N","exchange":"MEX","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"0QP5","exchange":"LTS","isin":"CH0012138530","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX1","exchange":"DUS","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Credit Suisse Group AG","symbol":"CSX1","exchange":"MUN","isin":"US2254011081","titleCount":0,"contentCount":1,"primary":true},{"name":"Media Sentiment Inc","symbol":"MSEZ","exchange":"PINX","isin":"US58448A2042","titleCount":0,"contentCount":1,"primary":true}],"author":{"name":"Tatum Peregrin","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Ledger Gazette","homeUrl":"https://ledgergazette.com","category":"Trade","editorialRank":"3","industry":"Banking & Finance","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"599564993","name":"Ledger Gazette","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"1137"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Business"],"genre":"General"}},"es_id":86994222}